Omalizumab biosimilar (Genescience Pharmaceutical)

奥马珠单抗生物类似药（金赛药业）

Report date: 2022/09/29 11:27:41

Base Information

Drug NameOmalizumab biosimilar (Genescience Pharmaceutical)
Drug Alias Name奥马佐单抗生物类似药 (金赛药业）Gensci-069
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionImmunoglobulin E inhibitors
TargetsImmunoglobulin E
Therapy Area/IndicationsAllergic asthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChangchun GeneScience Pharmaceuticals Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesChangchun GeneScience Pharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsAllergic asthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A